Key Findings About HCV Genotype 3
Regimens Containing Gilead’s Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3
Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group
BURLINGTON, Mass., April 1, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of hepatitis C virus (HCV) genotype-3 infected patients with cirrhosis of the liver achieving a sustained virologic response (SVR) is one of the attributes that most influences their prescribing decisions. Clinical data and interviewed experts indicate that interferon-free regimens containing Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s NS5A inhibitor daclatasvir have convenience and efficacy advantages over currently available regimens for HCV genotype-3 infections. However, competition from other NS5A inhibitors, such as Gilead’s GS-5816, may constrain uptake of daclatasvir.
Continue reading this entire article: